Profile data is unavailable for this security.
About the company
Shanghai Yizhong Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development and industrialization of new and improved anti-tumor drugs. The Company's main products include paclitaxel micelles, docetaxel micelles and cabazitaxel micelles. Paclitaxel micelles are products under development that have been submitted for registration and marketing applications, and their indications are non-small cell lung cancer. Docetaxel micelles and cabazitaxel micelles are products under development in the pre-clinical research stage.
- Revenue in CNY (TTM)336.56m
- Net income in CNY135.71m
- Incorporated2009
- Employees43.00
- LocationShanghai Yizhong Pharmaceutical Co LtdNo. 79 Renqi Road, Fengxian DistrictSHANGHAI ChinaCHN
- Phone+86 2 137190005
- Fax+86 2 137190005
- Websitehttps://www.yizhongpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Hile Bio-Technology Co Ltd | 239.79m | 44.92m | 3.99bn | 295.00 | 90.58 | 3.19 | -- | 16.63 | 0.0669 | 0.0669 | 0.3664 | 1.90 | 0.154 | 1.06 | 2.40 | 812,857.50 | 2.06 | 1.73 | 2.56 | 2.47 | 45.19 | 50.44 | 13.37 | 10.37 | 1.16 | -- | 0.0562 | 23.89 | -19.76 | -1.11 | -48.30 | 24.17 | -41.32 | 23.47 |
| Yabao Pharmaceutical Group Co Ltd | 2.88bn | 204.43m | 4.02bn | 4.14k | 20.26 | 1.38 | -- | 1.39 | 0.2754 | 0.2754 | 3.81 | 4.05 | 0.7193 | 2.98 | 6.79 | 695,432.10 | 4.52 | 2.82 | 5.90 | 3.97 | 56.00 | 59.20 | 6.29 | 4.19 | 1.62 | 47.13 | 0.0675 | 43.74 | 7.05 | -0.0572 | 90.71 | -6.10 | 7.98 | -9.71 |
| Jiangsu Jibeier Pharmaceutical Co Ltd | 889.82m | 233.59m | 4.04bn | 1.45k | 16.54 | 1.99 | -- | 4.55 | 1.24 | 1.24 | 4.74 | 10.37 | 0.426 | 3.13 | 5.33 | 615,794.80 | 11.17 | 9.77 | 12.06 | 10.66 | 87.87 | 88.44 | 26.22 | 23.29 | 6.76 | -- | 0.005 | 30.68 | 31.49 | 12.16 | 41.65 | 17.79 | 112.78 | -- |
| Shanghai Haixin Group Co Ltd | 1.11bn | 171.70m | 4.17bn | 760.00 | 32.56 | 1.41 | -- | 3.76 | 0.1422 | 0.1422 | 0.9185 | 3.27 | 0.2246 | 7.19 | 9.32 | 1,458,849.00 | 4.05 | 2.68 | 4.57 | 3.06 | 46.37 | 44.55 | 18.02 | 11.17 | 2.83 | -- | 0.0089 | 36.10 | -17.88 | 1.48 | 1.20 | 4.19 | -10.27 | 13.18 |
| ZhuZhou QianJin Pharmaceutical Co., Ltd | 3.84bn | 322.70m | 4.21bn | 5.34k | 13.15 | 1.70 | -- | 1.10 | 0.7546 | 0.7546 | 8.94 | 5.82 | 0.8283 | 3.58 | 9.76 | 719,592.90 | 8.61 | 8.99 | 16.26 | 16.21 | 45.46 | 44.59 | 10.40 | 10.03 | 1.95 | -- | 0.1297 | 68.27 | -5.66 | 2.68 | 5.53 | 4.64 | -1.06 | -2.64 |
| Pulike Biological Engineering Inc | 1.18bn | 136.36m | 4.21bn | 1.68k | 30.82 | 1.54 | -- | 3.56 | 0.3946 | 0.3946 | 3.39 | 7.91 | 0.359 | 2.39 | 2.65 | 704,310.60 | 4.14 | 7.64 | 4.81 | 8.96 | 60.96 | 62.57 | 11.53 | 17.85 | 2.58 | 148.40 | 0.0146 | 52.48 | 1.84 | 15.55 | 3.99 | 5.17 | 41.58 | 18.47 |
| Shanghai Yizhong Pharmaceutical Co Ltd | 336.56m | 135.71m | 4.29bn | 43.00 | 31.62 | 2.86 | -- | 12.76 | 0.66 | 0.66 | 1.64 | 7.28 | 0.2219 | 0.9416 | 3.28 | 7,826,913.00 | 8.95 | -0.9181 | 9.39 | -0.9485 | 93.54 | 93.19 | 40.32 | -6.11 | 12.66 | -- | 0.0342 | -- | 52.68 | -- | 13.09 | -- | 20.44 | -- |
| Shanghai Haoyuan Chemexpress Co Ltd | 1.97bn | 97.97m | 4.36bn | 3.37k | 44.51 | 1.72 | -- | 2.22 | 0.4658 | 0.4658 | 9.36 | 12.08 | 0.4845 | 1.01 | 3.91 | 583,547.80 | 2.38 | 7.38 | 3.23 | 9.60 | 42.51 | 47.03 | 4.92 | 13.53 | 0.894 | 3.37 | 0.3013 | 14.37 | 38.44 | 44.33 | -34.18 | 47.24 | 48.95 | -- |
| Zhejiang Shouxiangu Pharmaceuticl Co Ltd | 799.09m | 269.00m | 4.38bn | 1.14k | 16.08 | 1.92 | -- | 5.48 | 1.37 | 1.37 | 4.08 | 11.49 | 0.2573 | 0.9016 | 6.83 | 699,118.90 | 8.66 | 10.04 | 10.48 | 11.63 | 81.31 | 83.66 | 33.66 | 28.29 | 3.33 | -- | 0.2547 | 47.86 | -5.39 | 8.93 | -8.39 | 18.78 | 12.23 | 17.13 |
Data as of Jul 26 2024. Currency figures normalised to Shanghai Yizhong Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
4.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 1.52m | 1.01% |
| JPMorgan Asset Management (China) Co Ltd.as of 31 Dec 2023 | 1.36m | 0.90% |
| First Seafront Fund Management Co., Ltd.as of 31 Dec 2023 | 913.84k | 0.61% |
| Cinda Fund Management Co. Ltd.as of 31 Dec 2023 | 786.34k | 0.52% |
| Bank of China Investment Management Co., Ltd.as of 31 Dec 2023 | 647.28k | 0.43% |
| Maxwealth Fund Management Co., Ltd.as of 31 Dec 2023 | 536.14k | 0.36% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 459.33k | 0.30% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 437.78k | 0.29% |
| Hwabao WP Fund Management Co., Ltd.as of 31 Dec 2023 | 411.35k | 0.27% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 273.77k | 0.18% |
More ▼
Data from 31 Dec 2023 - 27 Jun 2024Source: FactSet Research Systems Inc.
